ECSP22066678A - Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio. - Google Patents
Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio.Info
- Publication number
- ECSP22066678A ECSP22066678A ECSENADI202266678A ECDI202266678A ECSP22066678A EC SP22066678 A ECSP22066678 A EC SP22066678A EC SENADI202266678 A ECSENADI202266678 A EC SENADI202266678A EC DI202266678 A ECDI202266678 A EC DI202266678A EC SP22066678 A ECSP22066678 A EC SP22066678A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical compositions
- quinazolin
- piperazin
- methoxyphenyl
- trifluoromethyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 229910001415 sodium ion Inorganic materials 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000000536 complexating effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- FWYSMLBETOMXAG-QHCPKHFHSA-N letermovir Chemical compound COC1=CC=CC(N2CCN(CC2)C=2N([C@@H](CC(O)=O)C3=CC=CC(F)=C3N=2)C=2C(=CC=C(C=2)C(F)(F)F)OC)=C1 FWYSMLBETOMXAG-QHCPKHFHSA-N 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a nuevas composiciones farmacéuticas estables que contienen ácido 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il] acético e iones de sodio que están esencialmente libres de agentes solubilizantes formadores de complejos, tales como PEG, ciclodextrina, lisina, arginina, en particular HPBCD. La invención se refiere además a métodos de preparación de dichas composiciones farmacéuticas. La invención se refiere además al uso de dichas composiciones farmacéuticas en métodos de tratamiento y/o como profiláctico de enfermedades, particularmente su uso como un antivírico, preferentemente contra citomegalovirus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20159711 | 2020-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22066678A true ECSP22066678A (es) | 2022-12-30 |
Family
ID=69742713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202266678A ECSP22066678A (es) | 2020-02-27 | 2022-08-24 | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230138444A1 (es) |
| EP (1) | EP4110291A1 (es) |
| JP (1) | JP7590444B2 (es) |
| KR (1) | KR20220148862A (es) |
| CN (1) | CN115515565A (es) |
| AR (1) | AR121438A1 (es) |
| AU (1) | AU2021227276B2 (es) |
| BR (1) | BR112022016868A2 (es) |
| CA (1) | CA3169260A1 (es) |
| CL (1) | CL2022002293A1 (es) |
| CO (1) | CO2022012092A2 (es) |
| CU (1) | CU20220051A7 (es) |
| EC (1) | ECSP22066678A (es) |
| IL (1) | IL295765A (es) |
| MX (1) | MX2022010444A (es) |
| PE (1) | PE20230514A1 (es) |
| PH (1) | PH12022552257A1 (es) |
| PY (1) | PY2116975A (es) |
| TW (1) | TWI884223B (es) |
| UA (1) | UA129169C2 (es) |
| UY (1) | UY39095A (es) |
| WO (1) | WO2021170875A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY40078A (es) * | 2021-12-21 | 2023-06-30 | Aic246 Ag & Co Kg | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin |
| CN114942278B (zh) * | 2022-04-12 | 2023-09-08 | 山东诚创蓝海医药科技有限公司 | 来特莫韦中间体二d-(+)-二对甲基苯甲酰酒石酸乙酸乙酯络合物有关物质的分析方法 |
| CN119745803A (zh) * | 2024-12-30 | 2025-04-04 | 上海奥科达医药科技股份有限公司 | 一种来特莫韦制剂组合物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| DE102012101680A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| WO2014047562A2 (en) * | 2012-09-21 | 2014-03-27 | Epiphany Biosciences | Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain |
| CN109966244A (zh) * | 2017-12-27 | 2019-07-05 | 天津耀辰实业发展有限公司 | 一种含有乐特莫韦的药物组合物 |
-
2021
- 2021-02-26 AR ARP210100496A patent/AR121438A1/es unknown
- 2021-02-26 UY UY0001039095A patent/UY39095A/es unknown
- 2021-02-26 PY PY202102116975A patent/PY2116975A/es unknown
- 2021-03-01 KR KR1020227033587A patent/KR20220148862A/ko active Pending
- 2021-03-01 IL IL295765A patent/IL295765A/en unknown
- 2021-03-01 MX MX2022010444A patent/MX2022010444A/es unknown
- 2021-03-01 WO PCT/EP2021/055057 patent/WO2021170875A1/en not_active Ceased
- 2021-03-01 UA UAA202203497A patent/UA129169C2/uk unknown
- 2021-03-01 PE PE2022001821A patent/PE20230514A1/es unknown
- 2021-03-01 CU CU2022000051A patent/CU20220051A7/es unknown
- 2021-03-01 CN CN202180016533.7A patent/CN115515565A/zh active Pending
- 2021-03-01 AU AU2021227276A patent/AU2021227276B2/en active Active
- 2021-03-01 EP EP21708006.8A patent/EP4110291A1/en active Pending
- 2021-03-01 CA CA3169260A patent/CA3169260A1/en active Pending
- 2021-03-01 PH PH1/2022/552257A patent/PH12022552257A1/en unknown
- 2021-03-01 US US17/802,558 patent/US20230138444A1/en active Pending
- 2021-03-01 BR BR112022016868A patent/BR112022016868A2/pt unknown
- 2021-03-01 JP JP2022551669A patent/JP7590444B2/ja active Active
- 2021-03-02 TW TW110107366A patent/TWI884223B/zh active
-
2022
- 2022-08-22 CL CL2022002293A patent/CL2022002293A1/es unknown
- 2022-08-24 CO CONC2022/0012092A patent/CO2022012092A2/es unknown
- 2022-08-24 EC ECSENADI202266678A patent/ECSP22066678A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021170875A1 (en) | 2021-09-02 |
| MX2022010444A (es) | 2022-10-18 |
| KR20220148862A (ko) | 2022-11-07 |
| CU20220051A7 (es) | 2023-04-10 |
| TWI884223B (zh) | 2025-05-21 |
| AU2021227276B2 (en) | 2025-02-13 |
| AR121438A1 (es) | 2022-06-08 |
| PH12022552257A1 (en) | 2023-11-20 |
| NZ792665A (en) | 2025-09-26 |
| CL2022002293A1 (es) | 2023-02-03 |
| PY2116975A (es) | 2022-04-05 |
| AU2021227276A1 (en) | 2022-10-20 |
| EP4110291A1 (en) | 2023-01-04 |
| PE20230514A1 (es) | 2023-03-24 |
| US20230138444A1 (en) | 2023-05-04 |
| CN115515565A (zh) | 2022-12-23 |
| CA3169260A1 (en) | 2021-09-02 |
| UA129169C2 (uk) | 2025-01-29 |
| JP2023520976A (ja) | 2023-05-23 |
| IL295765A (en) | 2022-10-01 |
| JP7590444B2 (ja) | 2024-11-26 |
| TW202140020A (zh) | 2021-11-01 |
| BR112022016868A2 (pt) | 2023-02-28 |
| UY39095A (es) | 2021-09-30 |
| CO2022012092A2 (es) | 2022-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22066678A (es) | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio. | |
| Ghaffari et al. | Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine | |
| CY1124690T1 (el) | Σκευασματα ενδοφλεβιου διαλυματος ποσακοναζολης σταθεροποιημενα με υποκατεστημενη βητα-κυκλοδεξτρινη | |
| EA200870219A1 (ru) | Стабилизированные сукцинатом витамина е фармацевтические композиции, способы их получения и применения | |
| HRP20201268T1 (hr) | Stabilne formulacije koje sadrže anti-pcsk9 antitijela | |
| BRPI0508854A (pt) | sais farmacêuticos de ácido-3-o-(3',3'-dimetilsuccinil) betulìnico | |
| EA031209B9 (ru) | Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения | |
| EA201390826A1 (ru) | ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA | |
| CO2024008041A2 (es) | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio | |
| NZ628444A (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| Fletcher et al. | A novel antiviral formulation inhibits a range of enveloped viruses | |
| EP2257161A4 (en) | AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA | |
| MA35158B1 (fr) | Formulations topiques de type suspension comprenant un depsipeptide cyclique | |
| ECSP22066676A (es) | 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo | |
| MX2024010899A (es) | Formulación acuosa estable de un anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm. | |
| UY39083A (es) | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria | |
| ECSP24048447A (es) | Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio | |
| Kim et al. | Iris germanica L. Rhizome-Derived exosomes ameliorated dihydrotestosterone-damaged human follicle dermal papilla cells through the activation of Wnt/β-catenin pathway | |
| PY2116973A (es) | Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético | |
| AR119805A1 (es) | Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso | |
| JP2013538828A5 (es) | ||
| NZ608164A (en) | Formulations for bovine granulocyte colony stimulating factor and variants thereof | |
| Park et al. | Dodecyldimethylamine oxide may induce lysosomal-associated cell death: Potential lipotoxicity | |
| ECSP992954A (es) | Preparaciones farmaceuticas estabilizadas de gabapentina y proceso para prepararla |